Chemotherapy for Persistent Gestational Trophoblastic Disease
Author Information
Author(s): Dobson L S, Lorigan P C, Coleman R E, Hancock B W
Primary Institution: Gestational Trophoblastic Disease Centre, Weston Park Hospital, Sheffield, UK
Hypothesis
The study evaluates the efficacy and toxicity of MEA as first-line therapy and EA as second-line therapy for gestational trophoblastic disease.
Conclusion
The MEA and EA chemotherapy regimens are well tolerated and associated with high complete response rates without affecting future fertility.
Supporting Evidence
- The overall complete response rate was 85%, with 97% for EA and 75% for MEA.
- Fifty-four percent of patients went on to have a normal pregnancy.
- No patient has developed a second malignancy.
Takeaway
Doctors used two types of chemotherapy to treat a serious pregnancy-related disease, and most patients got better without harming their ability to have babies later.
Methodology
Retrospective analysis of 73 patients treated with MEA and EA chemotherapy regimens.
Limitations
The study is retrospective and may not account for all variables affecting outcomes.
Participant Demographics
Patients treated since 1986 at a supra-regional centre, with a median follow-up of 5.5 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website